Updates are available Correction dated 2024-01-03
Click to view Correction: https://doi.org/10.1186/s12951-023-02269-4
-
Authors
Ren, Jimin
Dewey, Richard B. III
Rynders, Austin
Evan, Jacob
Evan, Jeremy
Ligozio, Shelia
Ho, Karen S.
Sguigna, Peter V.
Glanzman, Robert
Hotchkin, Michael T.
Dewey, Richard B. Jr.
Greenberg, Benjamin M.
-
Funding
Funding for this research was provided by:
Clene Nanomedicine, Inc.
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 2 December 2023
First Online: 13 December 2023
Change Date: 3 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12951-023-02269-4
Declarations
:
: JR, RBDIII, and RBD Jr have no competing interests to declare. AR, JaE, JeE, KSH, RG, MTH and BMG are employees of Clene and own stock in the company. At the time of study conductance, BMG was solely affiliated with UTSW. He was employed by Clene as a consultant after the conclusion of the described studies. SL is an employee of the contract research organization, Instat. PS has no disclosures related to this publication. He has received consulting fees from Medical Logix LLC, Genentech, and Bristol Myers Squibb.
: Study protocols were reviewed and approved by the Institutional Review Board of the University of Texas Southwestern Medical Center (IRB# STU-2019-0992 and STU-2019-0625, for REPAIR-MS and REPAIR-PD, respectively). Trials were conducted in accordance with Good Clinical Practice Guidelines of the International Conference on Harmonization and the ethical principles of the Helsinki Declaration of 1975, as revised in 2000 [CitationRef removed]. REPAIR-PD was registered on clinicaltrials.gov with registration number NCT03815916 and REPAIR-MS with registration number NCT03993171 prior to the enrollment of the first participants for each trial. All participants provided written consent prior to participating in the study.
: Not applicable.
